<!-- SOURCE TRACE
Template section: 2.1.2 - Therapeutic Indications
Required sources: IB 6.1
Verification status: NOT VERIFIED
Missing inputs: Source verification
-->

# 1.2.1.1 Therapeutic Indications

**Page range:** 12â€“13

```text
1.2.1.1
Therapeutic Indications6
Non-Small Cell Lung Cancer
Pralsetinib is indicated for the treatment of adult patients with RET fusion-positive, locally
advanced or metastatic NSCLC (Gavreto CDS).
Thyroid cancer
Pralsetinib is indicated for the treatment of adult and pediatric patients 12 years of age
and older with locally advanced or metastatic RET-mutant Medullary Thyroid Cancer
(MTC) who require systemic therapy and locally advanced or metastatic RET fusion-

5 For the purposes of this report, MAH refers exclusively to Roche, and MAH actions exclusively apply to
Roche, as there are additional MAHs for Gavreto globally. For actions relating to clinical studies and clinical
development, this refers to ongoing clinical studies where Roche/Genentech is the study sponsor.  For
actions relating to CDS, local labels, and DHCP, this exclusively relates to territories where Roche is the
legal MAH, and/or conducts compassionate use programs or post-trial access
6 Approved indications Countrywide: EU only has NSCLC and US only has NSCLC and TC (not MTC).

13
Drug Safety Report No: 1132062
positive thyroid cancer who require systemic therapy and who are radioactive iodine-
refractory (if radioactive iodine is appropriate) (Gavreto CDS).
```